GoAI
Get started
Arvinas, Inc. logo

Arvinas, Inc.

ARVN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$9.365

+$0.34 · +3.77%

Aug 21, 4:00 PM ET

ARVN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

61

Undervalued

Momentum

25

Weakening

Sentiment

63

Bullish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $9.365

52-week range

Current $9.365

Open
$9.15
Previous close
$9.025
Volume
951.75K
Market cap
604.24M USD
50-day average
$8.3418
+12.27% above average
200-day average
$10.5939
-11.60% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
635.71M USD
P/E (TTM)
49.29×
P/B (TTM)
1.08×
P/S (TTM)
1.91×
EV / EBITDA
-8.44×
Earnings yield
-10.50%
Free cash flow yield
-35.82%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
96.43%
Operating margin
-4.45%
Net margin
2.94%
Return on equity
-18.63%
Return on assets
-11.26%
Return on invested capital
-19.91%

Financial health

Debt / equity
0.01×
Current ratio
4.92×
Altman Z-score
1.58
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends161%-83%-328%-573%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 98.02%Operating margin, FY2021: -351.49%Operating margin, FY2022: -200.30%Operating margin, FY2023: -511.46%Operating margin, FY2024: -94.99%Operating margin, FY2025: -43.75%Net margin, FY2021: -356.34%Net margin, FY2022: -214.99%Net margin, FY2023: -467.90%Net margin, FY2024: -75.51%Net margin, FY2025: -30.77%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 98.02%. Operating margin FY2021 -351.49%. Operating margin FY2022 -200.30%. Operating margin FY2023 -511.46%. Operating margin FY2024 -94.99%. Operating margin FY2025 -43.75%. Net margin FY2021 -356.34%. Net margin FY2022 -214.99%. Net margin FY2023 -467.90%. Net margin FY2024 -75.51%. Net margin FY2025 -30.77%.

Income trends

Revenue

262.6M USD-0.30%

Operating income

−114.9M USD+54.08%

Net income

−80.8M USD+59.38%
Income trends across reported periods329.89M USD63.93M USD−202.03M USD−467.99M USDRevenue, FY2021: 53.6M USDRevenue, FY2022: 131.4M USDRevenue, FY2023: 78.5M USDRevenue, FY2024: 263.4M USDRevenue, FY2025: 262.6M USDOperating income, FY2021: −188.4M USDOperating income, FY2022: −263.2M USDOperating income, FY2023: −401.5M USDOperating income, FY2024: −250.2M USDOperating income, FY2025: −114.9M USDNet income, FY2021: −191M USDNet income, FY2022: −282.5M USDNet income, FY2023: −367.3M USDNet income, FY2024: −198.9M USDNet income, FY2025: −80.8M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 53.6M USD. Revenue FY2022 131.4M USD. Revenue FY2023 78.5M USD. Revenue FY2024 263.4M USD. Revenue FY2025 262.6M USD. Operating income FY2021 −188.4M USD. Operating income FY2022 −263.2M USD. Operating income FY2023 −401.5M USD. Operating income FY2024 −250.2M USD. Operating income FY2025 −114.9M USD. Net income FY2021 −191M USD. Net income FY2022 −282.5M USD. Net income FY2023 −367.3M USD. Net income FY2024 −198.9M USD. Net income FY2025 −80.8M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue262.6M USD263.4M USD78.5M USD131.4M USD53.6M USD
Cost of goods sold5.2M USD————
Gross profit257.4M USD263.4M USD78.5M USD131.4M USD53.6M USD
Research and development282.9M USD348.2M USD379.7M USD315M USD180.4M USD
Selling, general, and administrative89.4M USD165.4M USD100.3M USD79.6M USD61.6M USD
Operating expenses372.3M USD513.6M USD480M USD394.6M USD242M USD
Interest income22M USD54.8M USD38.8M USD12M USD1.8M USD
Interest expense————100K USD
Depreciation and amortization5.2M USD6.6M USD6.7M USD8.2M USD6M USD
Operating income−114.9M USD−250.2M USD−401.5M USD−263.2M USD−188.4M USD
Net income−80.8M USD−198.9M USD−367.3M USD−282.5M USD−191M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+91.54%
11 comparable reports
Latest EPS result
2.58
Estimate -0.37 · Beat by 789.64%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.871.450.03-1.39Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 11, 2025: actual -0.63, estimate -1.07, surprise +41.12%, Beat. Q2 2025, reported May 1, 2025: actual 1.14, estimate -0.86, surprise +232.56%, Beat. Q3 2025, reported Aug 6, 2025: actual -0.84, estimate -0.87, surprise +3.45%, Beat. Q4 2025, reported Nov 5, 2025: actual -0.48, estimate -0.75, surprise +36.00%, Beat. Q1 2026, reported Feb 24, 2026: actual -1.1, estimate -0.55, surprise -100.00%, Miss. Q2 2026, reported May 12, 2026: actual -0.9, estimate -0.95, surprise +5.26%, Beat. Q3 2026, reported Aug 4, 2026: actual 2.58, estimate -0.374, surprise +789.64%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.855, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates268.92M181.97M95.02M8.08MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 11, 2025: actual 59.2M USD, estimate 42.53M USD, surprise +39.19%, Beat. Q2 2025, reported May 1, 2025: actual 188.8M USD, estimate 42.31M USD, surprise +346.28%, Beat. Q3 2025, reported Aug 6, 2025: actual 22.4M USD, estimate 25M USD, surprise -10.40%, Miss. Q4 2025, reported Nov 5, 2025: actual 41.9M USD, estimate 37.26M USD, surprise +12.44%, Beat. Q1 2026, reported Feb 24, 2026: actual 9.5M USD, estimate 37.25M USD, surprise -74.50%, Miss. Q2 2026, reported May 12, 2026: actual 15.6M USD, estimate 16.61M USD, surprise -6.09%, Miss. Q3 2026, reported Aug 4, 2026: actual 249.7M USD, estimate 60.71M USD, surprise +311.31%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 17.39M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

26 ratings
Strong buy00%
Buy1973%
Hold623%
Sell14%
Strong sell00%

Recent analyst actions

12 institutions

ARVN news

zacks.com

Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know

Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read source
defenseworld.net

Arvinas Q2 Earnings Call Highlights

Arvinas (NASDAQ: ARVN) said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the…

Read source
seekingalpha.com

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Arvinas Q2 Earnings Call Highlights

Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the…

Read source
zacks.com

Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates

Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share a year ago.

Read source
globenewswire.com

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data…

Read source

ARVN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ARVN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
15.42M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
13.78M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
7.08M
Weight
1.26%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.07M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
4.55M
Weight
0.03%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
3.97M
Weight
0.06%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
3.64M
Weight
0.03%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
2.75M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research ARVN

research.disclaimer